Baird Medical Dismisses Auditor Marcum Asia

Ticker: BDMDW · Form: 6-K · Filed: Jan 28, 2025 · CIK: 1982444

Baird Medical Investment Holdings Ltd 6-K Filing Summary
FieldDetail
CompanyBaird Medical Investment Holdings Ltd (BDMDW)
Form Type6-K
Filed DateJan 28, 2025
Risk Levelmedium
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: auditor-change, regulatory-filing

TL;DR

Baird Medical just fired its auditor, Marcum Asia. Big changes coming?

AI Summary

Baird Medical Investment Holdings Limited announced on January 24, 2025, the dismissal of its former independent registered public accounting firm, Marcum Asia CPAs LLP. This decision was approved by the Company's Board of Directors and its Audit Committee.

Why It Matters

A change in auditor can sometimes signal underlying issues or a strategic shift within a company, potentially impacting investor confidence.

Risk Assessment

Risk Level: medium — A change of auditor, especially without immediate explanation, can introduce uncertainty about the company's financial reporting and internal controls.

Key Players & Entities

  • Baird Medical Investment Holdings Limited (company) — Registrant
  • Marcum Asia CPAs LLP (company) — Former independent registered public accounting firm
  • January 24, 2025 (date) — Date of auditor dismissal

FAQ

What is the primary reason for the dismissal of Marcum Asia CPAs LLP?

The filing does not explicitly state the reason for the dismissal of Marcum Asia CPAs LLP, only that the decision was made and approved by the Board and Audit Committee.

When was the dismissal of Marcum Asia CPAs LLP effective?

The dismissal of Marcum Asia CPAs LLP was effective on January 24, 2025.

Who approved the dismissal of the auditor?

The dismissal was approved by the board of directors of Baird Medical Investment Holdings Limited and the audit committee of the Board.

Is Baird Medical Investment Holdings Limited required to file annual reports under Form 20-F or 40-F?

The filing indicates that the registrant files or will file annual reports under cover of Form 20-F.

What is the principal executive office address of Baird Medical Investment Holdings Limited?

The principal executive offices are located at Room 202, 2/F, Baide Building, Building 11, No.15 Rongtong Street, Yuexiu District, Guangzhou, Peoples Republic of China.

Filing Stats: 621 words · 2 min read · ~2 pages · Grade level 14.4 · Accepted 2025-01-28 06:02:03

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number 001-42300 Baird Medical Investment Holdings Limited Room 202, 2/F, Baide Building, Building 11, No.15 Rongtong Street, Yuexiu District, Guangzhou, Peoples Republic of China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Change of Auditor On January 24, 2025, Baird Medical Investment Holdings Limited (the “Company”), upon the approval and ratification of the board of directors of the Company (the “Board”) and the audit committee of the Board (the “Audit Committee”), dismissed Marcum Asia CPAs LLP (“Marcum Asia”), the former independent registered public accounting firm of the Company, effective on January 24, 2025, and appointed Kreit & Chiu CPA LLP (PCAOB ID: 6651) (the “New Auditor”) to serve as its independent registered public accounting firm, effective on January 24, 2025, for the year ended December 31, 2024. Marcum Asia’s reports on the Company’s financial statements for the fiscal years ended December 31, 2023 and 2022 did not contain any adverse opinion or disclaimers of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles. Furthermore, during the fiscal years ended December 31, 2023 and 2022 and through January 24, 2025, there were no disagreements, as defined in Item 16F(a)(1)(iv) of Form 20-F, with Marcum Asia on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum Asia, would have caused Marcum Asia to make reference to the subject matter of the disagreements in connection with its reports on the Company’s financial statements for such year. In addition, during this time, there were no “reportable events,” as defined in as defined in Item 16F(a)(1)(v)(A)-(D) of Form 20-F, except for the material weaknesses related to the Company’s internal control over financial reporting, including (i) lack of sufficient financial reporting and accounting personnel with appropriate knowledge of U.S. GAAP and SEC reporting requirements to properly address certain accounting issues and to prepare and review financial statements and related disclosures in accordance with U.S. GAAP and SEC reporting requirements; and (ii) lack of comprehensive accounting policies and procedures manual in accordance with U.S. GAAP and documented controls which enable management and other personnel to understand and carry out their internal control responsibilities. The Company provided Marcum Asia with a copy of the above disclosure and requested that Marcum Asia furnish the Company with a letter addressed to the U.S. Securities and Exchange Commission stating whether or not it agrees with the above statements. A copy of Marcum Asia’s letter is filed as Exhibit 16.1 to this Form 6-K. During the two most recent fiscal years and any subsequent interim periods prior to the engagement of the New Auditor, neither the Company, nor someone on behalf of the Company, has consulted the New Auditor regarding any of the matters described in Item 16F(a)(2)(i) and (ii) of Form 20-F. The New Auditor is aware of the material weaknesses described above and understands it is a reportable event. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 28, 2025 By: /s/ Haimei Wu Name: Haimei Wu Title: Chairwoman and Chief Executive Officer EXHIBIT INDEX Exhibit Number Description 16.1 Letter of Marcum Asia CPAs LLP to the U.S. Securities and Exchange Commission dated January 28, 2025

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.